Abstract
There are many types of colitis models in animals that researchers use to elucidate the mechanism of action of human inflammatory bowel disease (IBD). These models are also used to test novel therapeutics and therapeutic treatment regimens. Here, we will review the characteristics of the mdr1a−/− model of spontaneous colitis that we believe make this model an important part of the IBD researcher's toolbox. We will also share new data that will reinforce the fact that this model is relevant in the study of IBD. Mdrla−/− mice lack the murine multiple drug resistance gene for P-glyco-protein 170 that is normally expressed in multiple tissues including intestinal epithelial cells. These mice spontaneously develop a form of colitis at around 12 wk of age. The fact that the complexity of this model mirrors the complexity of disease in humans, as well as recent literature that links MDR1 polymorphisms in humans to Crohn's Disease and Ulcerative Colitis, makes this an appropriate animal model to study.
Similar content being viewed by others
References
Shanahan F: Crohn's disease. Lancet 2002;359:62–69.
Flynn C, Levine J, Rosenberg DW: Murine models of ulcerative colitis. Arch Pharm Res 2003;26:433–440.
Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10-deficient mice develop chronic enterocolitis. [see comments]. Cell 1993;75:263–274.
Watanabe M, Ueno Y, Yamazaki M, Hibi T: Mucosal IL-7-mediated immune responses in chronic colitis-IL-7 transgenic mouse model. Immunol Res 1999;20:251–259.
Morrissey PJ, Charrier K: Induction of wasting disease in SCID mice by the transfer of normal CD4+/CD45RBhi T cells and the regulation of this autoreactivity by CD4+/CD45RBlo T cells. Res Immunol 1994;145:357–362.
Pizarro TT, Arseneau KO, Bamias G, Cominelli F: Mouse models for the study of Crohn's disease. Trends Mol Med 2003;9:218–222.
Panwala CM, Jones JC, Viney JL: A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdrla, spontaneously develop colitis. J Immunol 1998;161:5733–5744.
Leveille-Webster CR, Arias IM: The biology of the P-glycoproteins. J Membr Biol 1995;143:89–102.
Chen CJ, Chin JE, Ueda K, et al.: Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381–389.
Hsu SI, Lothstein L, Horwitz SB: Differential overexpression of three mdr gene family members in multidrugresistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 1989;264:12053–12062.
Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I: The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 1987;262:505–508.
Croop JM, Raymond M, Haber D, et al.: The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989;9:1346–1350.
Sparreboom A, van Asperen J, Mayer U, et al.: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997;94:2031–2035.
Ho GT, Moodie FM, Satsangi J: Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003;52:759–766.
Valverde MA, Diaz M, Sepulveda FV, et al.: Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 1992;355:830–833.
Johnstone RW, Cretney E, Smyth MJ: P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999;93:1075–1085.
Johnstone RW, Ruefli AA, Smyth MJ: Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000;25:1–6.
Mahler M, Bristol IJ, Leiter EH, et al.: Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol 1998;274:G544–551.
Owen RJ: Helicobacter: species classification and identification. Br Med Bull 1998;54:17–30.
Haines DC, Gorelick PL, Battles JK, et al.: Inflammatory large bowel disease in immunodeficient rats naturally and experimentally infected with Helicobacter bilis. Vet Pathol 1998;35:202–208.
Kullberg MC, Rothfuchs AG, Jankovic D, et al.: Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. Infect Immun 2001;69:4232–4241.
Shomer NH, Dangler CA, Schrenzel MD, Fox JG: Helicobacter bilis-induced inflammatory bowel disease in scid mice with defined flora. Infect Immun 1997;65:4858–4864.
Maggio-Price L, Shows D, Wagge K, et al.: Helicobacter bilis infection accelerates, and Helicobacter hepaticus infection delays the development of colitis in multiple drug resistance (mdrla−/−) deficient mice. Am J Pathol 2002;160(2):739–751.
Eisenbraun MD, Miller RA: mdrla-encoded P-glycoprotein is not required for peripheral T cell proliferation, cytokine release, or cytotoxic effector function in mice. J Immunol 1999;163:2621–2627.
Eisenbraun MD, Mosley RL, Teitelbaum DH, Miller RA: Altered development of intestinal intraepithelial lymphocytes in P-glycoprotein-deficient mice. Dev Comp Immunol 2000;24:783–795.
D'Ambrosio D, Panina-Bordignon P, Sinigaglia F: Chemokine receptors in inflammation: an overview. J Immunol Methods 2003;273:3–13.
Herfarth H, Pollok-Kopp B, Goke M, et al.: Polymorphism of CC chemokine receptors CCR2 and CCR5 in Crohn's disease. Immunol Lett 2001;77:113–117.
MacDermott RP, Sanderson IR, Reinecker HC: The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflammatory Bowel Diseases 1998;4:54–67.
Papadakis KA, Targan SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann Rev Med 2000;51:289–298.
Reinecker HC, Steffen M, Witthoeft T, et al.: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174–181.
Wedemeyer J, Lorentz A, Goke M, et al.: Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa. [see comments]. Gut 1999;44:629–635.
McCormack G, Moriarty D, O'Donoghue DP, et al.: Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 2001;50:491–495.
Dwinell MB, Lugering N, Eckmann L, Kagnoff MF: Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. Gastroenterology 2001;120:49–59.
Yang SK, Eckmann L, Panja A, Kagnoff MF: Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells. Gastroenterology 1997;113:1214–1223.
Satsangi J, Parkes M, Louis E, et al.: Two stage genomewide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nature Genet 1996;14:199–202.
Schwab M, Schaeffeler E, Marx C, et al.: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124:26–33.
Yacyshyn B, Maksymowych W, Bowen-Yacyshyn MB: Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis. Human Immunol 1999;60:677–687.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wilk, J.N., Bilsborough, J. & Viney, J.L. The mdr1a−/− mouse model of spontaneous colitis. Immunol Res 31, 151–159 (2005). https://doi.org/10.1385/IR:31:2:151
Issue Date:
DOI: https://doi.org/10.1385/IR:31:2:151